6533b853fe1ef96bd12acd41
RESEARCH PRODUCT
Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)
Manfredi RizzoAlessandro CollettiPeter E. PensonNiki KatsikiDimitri P. MikhailidisPeter P. TothIoanna Gouni-bertholdJohn ManciniDavid MaraisPatrick MoriartyMassimiliano RuscicaAmirhossein SahebkarDragos VinereanuArrigo Francesco Giuseppe CiceroMaciej BanachJulio AcostaMutaz Al-khnifsawiFahad AlnouriFahma AmarAtanas G. AtanasovGani BajraktariMaciej BanachIoanna Gouni-bertholdSonu BhaskarAgata Bielecka-dąbrowaBojko BjelakovicEric BruckertIbadete BytyçiAlberto CafferataRichard CeskaArrigo F.g. CiceroKrzysztof ChlebusXavier ColletMagdalena DaccordOlivier DescampsDragan DjuricRonen DurstMarat V. EzhovZlatko FrasDan GaitaIoanna Gouni-bertholdAdrian V. HernandezSteven R. JonesJacek JozwiakNona KakauridzeAmani KallelNiki KatsikiAmit KheraKaram KostnerRaimondas KubiliusGustavs LatkovskisG.b. John ManciniA. David MaraisSeth S. MartinJulio Acosta MartinezMohsen MazidiDimitri P. MikhailidisErkin M. MirrakhimovAndre R. MiserezOlena MitchenkoNatalya P. MitkovskayaPatrick M. MoriartySeyed Mohammad NabaviDevaki NairDemosthenes B. PanagiotakosGyörgy ParaghDaniel PellaPeter E. PensonZaneta PetrulionieneMatteo PirroArman PostadzhiyanRaman PuriAshraf RedaŽEljko ReinerDina RadenkovicMichał RakowskiJemaa RiadhDimitri RichterManfredi RizzoMassimiliano RuscicaAmirhossein SahebkarMaria-corina SerbanAbdullah M.a ShehabAleksandr B. ShekCesare R. SirtoriClaudia StefanuttiTomasz TomasikPeter P. TothMargus ViigimaaPedro ValdivielsoDragos VinereanuBranislav VohnoutStephan Von HaehlingMichal VrablikNathan D. WongHung-i YehJiang ZhishengAndreas Zirliksubject
PharmacologySettore MED/04 - Patologia GeneraleNAFLDLiver steatosisPosition paperDietary supplements; Liver steatosis; NAFLD; Nutraceuticals; Position paper;NutraceuticalsDietary supplementsdescription
Non-Alcoholic Fatty Liver Disease (NAFLD) is a common condition affecting around 10–25% of the general adult population, 15% of children, and even > 50% of individuals who have type 2 diabetes mellitus. It is a major cause of liver-related morbidity, and cardiovascular (CV) mortality is a common cause of death. In addition to being the initial step of irreversible alterations of the liver parenchyma causing cirrhosis, about 1/6 of those who develop NASH are at risk also developing CV disease (CVD). More recently the acronym MAFLD (Metabolic Associated Fatty Liver Disease) has been preferred by many European and US specialists, providing a clearer message on the metabolic etiology of the disease. The suggestions for the management of NAFLD are like those recommended by guidelines for CVD prevention. In this context, the general approach is to prescribe physical activity and dietary changes the effect weight loss. Lifestyle change in the NAFLD patient has been supplemented in some by the use of nutraceuticals, but the evidence based for these remains uncertain. The aim of this Position Paper was to summarize the clinical evidence relating to the effect of nutraceuticals on NAFLD-related parameters. Our reading of the data is that whilst many nutraceuticals have been studied in relation to NAFLD, none have sufficient evidence to recommend their routine use; robust trials are required to appropriately address efficacy and safety.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2023-03-01 |